The total return over the past 12 months is +133.10% vs. +16.94% for the S&P 500. So far it's up +50.93% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +133.10% | +93.96% | +17.83% | +9.57% | N/A | N/A |
| Total Return CAGR | +133.10% | +93.96% | +17.83% | +9.57% | N/A | N/A |
| Revenue CAGR | +77.12% | +50.58% | +23.71% | +17.22% | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Travere Therapeutics, Inc. (TVTX)
| Year | Start price | End price | TVTX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $38.21 | $57.67 | +50.93% | +14.51% | +36.42% |
| 2025 | $17.42 | $38.21 | +119.35% | +17.72% | +101.63% |
| 2024 | $8.99 | $17.42 | +93.77% | +24.89% | +68.88% |
| 2023 | $21.03 | $8.99 | (57.25%) | +26.19% | (83.44%) |
| 2022 | $31.04 | $21.03 | (32.25%) | (18.17%) | (14.08%) |
| 2021 | $27.26 | $31.04 | +13.89% | +28.74% | (14.85%) |
| 2020 | $14.20 | $27.26 | +91.94% | +18.37% | +73.57% |
| 2019 | $22.63 | $14.20 | (37.25%) | +31.22% | (68.47%) |
| 2018 | $21.07 | $22.63 | +7.40% | (4.56%) | +11.96% |
| 2017 | $18.93 | $21.07 | +11.30% | +21.70% | (10.40%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
